Drug
Glofitamab clinical trials
Also written RO7082859 and Columvi.
- studies test it
- 63
- open now
- 39
- in phase 3
- 4
- first study started
- 2017
Keep track of what changes. Save the glofitamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Columvi
- 10
Studies by the year they started
63 studies that test it; most in 2026 (22)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 9 |
| 2025 | 11 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 49
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 51
Hoffmann-La Roche (11) · Ruijin Hospital (5) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (2) · The First Affiliated Hospital with Nanjing Medical University (2) · The First Affiliated Hospital of Soochow University (2)
Often tested with
Tested in the same studies.
Obinutuzumab (12) · Polatuzumab vedotin (7) · Lenalidomide (6) · Gemcitabine (5) · Oxaliplatin (5) · Rituximab (5) · Doxorubicin (3) · Prednisone (3)
Studies
Open first, then newest update. How each study uses glofitamab is read from its arms, and is right about nine times in ten.
Testing it · 63
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07888621Written as Glofitamab
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as Glofitamab
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingPhase 2Shanghai Zhongshan HospitalNCT07012980Written as Glofitamab
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Glofitamab
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2University of California, San FranciscoNCT06252675Written as Glofitamab
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06213311Written as Glofitamab
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07003295Written as Glofitamab
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as Glofitamab
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Glofitamab
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as Glofitamab
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07774234Written as Glofitamab
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")Not yet recruitingPhase 1National Cancer Institute (NCI)NCT07649304Written as Glofitamab
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT07749365Written as hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsNot yet recruitingPhase 2Joshua BrodyNCT07748364Written as Glofitamab
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06570447Written as Glofitamab
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06765317Written as Glofitamab
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07717177Written as Glofitamab
- A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOPNot yet recruitingPhase 2Yonsei UniversityNCT07702851Written as Polatuzumab vedotin, Glofitamab
- A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07599423Written as Glofitamab
- Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter SyndromeRecruitingPhase 2French Innovative Leukemia OrganisationNCT06186648Written as Glofitamab + Obinutuzumab
See all 63 studies that test glofitamab →
Given in every arm · 15 — glofitamab is usual care beside what is tested
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Glofitamab
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Glofitamab
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingPhase 2Hoffmann-La RocheNCT06806033Written as Glofitamab
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Hoffmann-La RocheNCT05533775Written as Glofitamab
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)RecruitingPhase 2Ryvu Therapeutics SANCT06534437Written as Glofitamab
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Glofitamab
- A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingPhase 1Arvinas Inc.NCT06393738Written as Glofitamab
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruitingPhase 2The Lymphoma Academic Research OrganisationNCT06558604Written as Glofitamab
- Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07613788Written as Glofitamab
- Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06996132Written as Glofitamab
- An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingPhase 1/2Hoffmann-La RocheNCT03533283Written as Glofitamab
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingPhase 1ADC Therapeutics S.A.NCT04970901Written as Glofitamab
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedPhase 1Hoffmann-La RocheNCT03467373Written as Glofitamab
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaTerminatedPhase 1Hoffmann-La RocheNCT05219513Written as Glofitamab
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04914741Written as Glofitamab
Codes
What other systems call glofitamab · ClinicalTrials.gg INT001741
- MeSH (NLM) C000720108glofitamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 06P3KLK2J8GLOFITAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q117846135glofitamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148486GlofitamabOne source FDA
- DrugBank DB16371One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720108 | glofitamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 06P3KLK2J8 | GLOFITAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q117846135 | glofitamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148486 | Glofitamab | One source FDA |
| DrugBank | DB16371 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.